Lifecore Biomedical, Inc.
LFCR
$6.38
$0.213.40%
NASDAQ
| 02/23/2025 | 11/24/2024 | 08/25/2024 | 05/26/2024 | 02/25/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.23% | 16.47% | 23.42% | 24.20% | 30.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.23% | 16.47% | 23.42% | 24.20% | 30.31% |
| Cost of Revenue | -2.74% | 2.26% | 5.80% | 14.78% | 35.89% |
| Gross Profit | 34.71% | 57.30% | 79.95% | 49.55% | 17.07% |
| SG&A Expenses | 15.24% | 13.38% | 12.05% | 0.73% | 21.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.44% | 5.35% | 7.27% | 9.15% | 28.50% |
| Operating Income | 35.17% | 59.27% | 66.46% | 69.69% | -15.86% |
| Income Before Tax | -122.28% | 67.82% | 108.29% | 114.88% | 34.86% |
| Income Tax Expenses | -110.00% | -44.89% | -82.14% | -40.58% | 2.62% |
| Earnings from Continuing Operations | -116.98% | 67.66% | 108.14% | 114.53% | 34.31% |
| Earnings from Discontinued Operations | -99.24% | 103.32% | 102.83% | 107.59% | 100.46% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.19% | 80.30% | 106.58% | 112.07% | 82.58% |
| EBIT | 35.17% | 59.27% | 66.46% | 69.69% | -15.86% |
| EBITDA | 70.48% | 99.19% | 98.94% | 124.35% | -518.43% |
| EPS Basic | -118.57% | 79.18% | 106.73% | 111.90% | 82.59% |
| Normalized Basic EPS | -670.23% | 48.94% | 124.05% | 131.90% | 120.69% |
| EPS Diluted | -75.87% | 76.05% | 101.53% | 106.85% | 78.30% |
| Normalized Diluted EPS | -5,114.50% | 42.18% | 112.23% | 119.06% | 102.35% |
| Average Basic Shares Outstanding | 9.46% | 4.23% | 1.70% | 2.03% | 1.91% |
| Average Diluted Shares Outstanding | -0.45% | 4.16% | 11.75% | 12.14% | 12.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |